Peripartum
Peripartum depression, including postpartum depression (PPD), is a significant mental health issue affecting new mothers, characterised by severe mood changes following childbirth. Current research into psychedelic treatments, particularly with compounds like esketamine and psilocybin, shows promising potential to alleviate depressive symptoms in this demographic.
What is Peripartum?
Peripartum depression, particularly postpartum depression, occurs in some women during pregnancy or within the first year after giving birth. The condition features symptoms such as persistent sadness, anxiety, irritability, and difficulty bonding with the baby, which can severely impact maternal and child health.
The pathophysiology of PPD is complex and may involve hormonal changes, genetic predisposition, and psychosocial factors. Neurobiological mechanisms, including alterations in serotonin and other neurotransmitter systems, have been implicated.
Symptoms of PPD can be debilitating, leading to difficulties in daily functioning. Without timely intervention, PPD can develop into chronic depression, adversely affecting both maternal health and child development.
Current Treatments
Standard-of-care treatments for postpartum depression typically include psychotherapy, such as cognitive behavioural therapy (CBT), and pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Peripartum.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Esketamine Multiple studies demonstrate significant improvements in PPD symptoms following esketamine administration. | Large | High | Consistent |
| Psilocybin Recent trials show promising results in its application for major depressive disorder, with potential implications for peripartum use. | Medium | Moderate | Consistent |
Esketamine and Peripartum
Esketamine, a nasal spray formulation, shows rapid antidepressant effects, particularly beneficial for mood disorders like postpartum depression. Studies have indicated that esketamine can lead to significant reductions in depressive symptoms just hours after administration, making it a valuable option for new mothers who may be at risk of severe mood disruptions following childbirth.
Psilocybin and Peripartum
Psilocybin has been researched for its ability to induce profound psychological effects, including mood elevation and emotional release. When applied in a therapeutic setting, psilocybin facilitates deep introspection and emotional processing, potentially allowing new mothers to address underlying issues connected to their postpartum experience and leading to sustained improvements in mood and psychological resilience.
Key Insights
- 1
New clinical trials indicate that a single dose of esketamine can significantly reduce depressive symptoms in postpartum patients.
- 2
Psilocybin therapy has shown efficacy in treating major depressive disorder, with implications for its use in peripartum depression.
- 3
Current research highlights the potential for psychedelic compounds to provide rapid relief from depressive symptoms compared to traditional pharmacological therapies.
Industrial Landscape
Key industry players include Reunion Neuroscience, which is conducting trials on the efficacy of psychedelics like RE104 in treating postpartum depression, and various non-profit organisations dedicated to advancing research in maternal mental health.
Quick Indicators
\"Ongoing clinical evaluations are investigating Peripartum as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Peripartum.